Micafungin
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Micafungin
- Micafungin: From Invasive Fungal Infections to Candida Urinary Tract Infection (Candiduria)
Micafungin: From Invasive Fungal Infections to Candida Urinary Tract Infection (Candiduria)
One-Sentence Summary
Micafungin is an echinocandin antifungal, originally developed for invasive fungal infections such as invasive/esophageal candidiasis. The TxGNN model predicts potential efficacy against urinary tract infection — specifically fungal UTI (candiduria) caused by Candida species — with 0 clinical trials but 13 supporting publications (case series, cohort studies, and case reports) currently available.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the regulatory dataset (drug is unlicensed in this jurisdiction). Based on known drug-class information, micafungin (echinocandin) is used for invasive fungal infections including invasive candidiasis and esophageal candidiasis. |
| Predicted New Indication | Urinary Tract Infection — specifically Candida spp. candiduria |
| TxGNN Prediction Score | 99.03% |
| Evidence Level | L3 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in the structured dataset. Based on known information, micafungin belongs to the echinocandin class of antifungals, which inhibits fungal 1,3-β-D-glucan synthase and disrupts fungal cell wall synthesis. Its efficacy in invasive candidiasis has been well established in prior clinical use, and mechanistically this same glucan-synthase inhibition is directly applicable to Candida-caused urinary tract infections (candiduria).
Importantly, the supporting literature makes clear that the TxGNN-predicted “urinary tract infection” is not a general bacterial UTI indication. Every publication retrieved describes fungal UTIs caused by Candida species (including C. glabrata, C. krusei, and the multidrug-resistant C. auris), often in patients with fluconazole-resistant organisms, indwelling catheters, transplant history, or neonatal/pediatric ICU exposure. This is mechanistically coherent: echinocandins target fungal cell walls, not bacterial pathogens, so their plausible therapeutic niche is specifically candiduria rather than bacterial UTI.
Notably, this candidate set also contained several lower-ranked TxGNN predictions (e.g., Ureaplasma urethritis, gonococcal urethritis, and four mesothelioma variants) that lack any mechanistic plausibility — echinocandins have no activity against cell-wall-free bacteria, peptidoglycan-based bacteria, or malignant tumor biology. These were appropriately screened to Hold (L5, no supporting evidence) and are excluded from further development consideration, reinforcing that the candiduria signal is a genuine, biologically grounded finding rather than embedding-space noise.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 27424599 | 2016 | Cohort/PK | Int J Antimicrob Agents | Urinary micafungin concentrations, despite low renal excretion, were sufficient to successfully treat Candida UTIs, including fluconazole-resistant species. |
| 27587066 | 2016 | Cohort | Int Urol Nephrol | Evaluated candiduria eradication rates among hospitalized patients treated with micafungin, an off-label use given low historical urinary penetration data. |
| 29109159 | 2018 | Multi-institutional cohort | Antimicrob Agents Chemother | Retrospective cohort of 305 hospitalized patients characterizing candiduria management patterns and antifungal overuse in asymptomatic cases. |
| 35146837 | 2022 | Case series (pediatric) | Pediatr Int | Reported treatment outcomes of micafungin in critically ill pediatric ICU patients with hospital-acquired Candida UTIs, with success rates by species. |
| 26937340 | 2016 | Case series | Med Mycol Case Rep | Five cases of candiduria treated with parenteral micafungin for ≥6 days, all achieving resolution within 30 days despite echinocandins’ low urinary concentration. |
| 39781278 | 2025 | Susceptibility survey | Ther Adv Infect Dis | Surveyed Candida species distribution and antifungal susceptibility (including micafungin) in vulvovaginal candidiasis and UTI cases in Vietnam. |
| 31111613 | 2019 | Case report | Transplant Infect Dis | Increased-dose micafungin successfully eradicated chronic symptomatic C. krusei UTI in a liver/kidney transplant recipient with limited antifungal options. |
| 38827222 | 2024 | Case report | Front Pediatr | Micafungin successfully treated C. glabrata urinary infection in a premature neonate with an indwelling urinary catheter. |
| 33520520 | 2020 | Case report | Cureus | Described management of multidrug-resistant C. auris UTI in a comorbid nursing home patient. |
| 38681664 | 2024 | Case report | Med Mycol Case Rep | Unilateral renal fungus ball caused by micafungin-susceptible C. glabrata, successfully managed with antifungal therapy plus endoscopic extraction. |
EU Market Information
Micafungin currently holds no marketing authorizations in this jurisdiction (market status: not marketed; total licenses: 0). No product/authorization records are available for review.
Safety Considerations
Please refer to the SmPC for safety information. Detailed warnings, contraindications, and drug interaction data were not available in this evidence pack (flagged as a Blocking data gap — TFDA label warnings/contraindications must be obtained before proceeding to safety assessment).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple cohort studies, case series, and case reports (13 publications, L3 evidence) consistently and mechanistically support micafungin’s use specifically for Candida-caused urinary tract infections (candiduria), particularly in fluconazole-resistant or multidrug-resistant cases. However, no controlled clinical trials exist, the drug is unlicensed in this jurisdiction, and critical safety label data (warnings/contraindications) are missing — this is a Blocking gap that must be resolved before any safety-related decision.
To proceed, the following is needed:
- TFDA label warnings/contraindications (Blocking gap DG001) — required before S1 safety pre-assessment can begin
- Formal mechanism-of-action documentation from DrugBank (High-priority gap DG002)
- A prospective study or registry specifically targeting Candida-confirmed UTI (candiduria), not general/bacterial UTI populations
- Explicit diagnostic scoping in any future indication label to exclude bacterial UTI, given the mechanism is fungal-cell-wall-specific
- Regulatory pathway review, since micafungin currently holds zero authorizations in this market
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.